DAAM2-AS1: A Potential Drug Target and Biomarker (G100505635)

Target Name: DAAM2-AS1

NCBI ID: G100505635

DAAM2-AS1

Other Name(s): DAAM2 antisense RNA 1

DAAM2-AS1: A Potential Drug Target and Biomarker

DAAM2-AS1, a protein expressed in the endoplasmic reticulum (ER), has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Its unique structure and function make it an attractive target for drug development.

DAAM2-AS1 functions as a protein-protein interaction (PPI) partner, which plays a critical role in regulating protein interactions and modulating cellular signaling pathways. It is a member of the DAAM2 family, which includes several structurally similar proteins that share a conserved catalytic core and a unique N-terminus. The DAAM2 family is known to play a central role in the regulation of various cellular processes, including protein folding, stability, and degradation.

DAAM2-AS1 is expressed in various tissues and cells, including brain, spinal cord, heart, and blood vessels. It is also highly expressed in neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. In these disorders, DAAM2-AS1 is involved in the formation of neurofibrillary tangles and the loss of neurotransmitter-associated protein (NACP) in the brain, which are thought to contribute to the progressive neurodegeneration.

Furthermore, DAAM2-AS1 has also been implicated in the development and progression of cancer. It has been observed to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. In addition, it is involved in the regulation of cell signaling pathways, which are often disrupted in cancer cells. This suggests that DAAM2-AS1 may play a critical role in the development and progression of cancer.

DAAM2-AS1 is also a potential biomarker for various diseases, including neurodegenerative disorders and cancer. Its expression is often reduced in these diseases, which may be used as a diagnostic or predictive marker. For example, reduced DAAM2-AS1 expression has been observed in individuals with Alzheimer's disease, and this may be a potential diagnostic biomarker for this disorder. Similarly, DAAM2-AS1 has been implicated in the development of cancer, and reduced expression of this protein has been observed in various types of cancer.

In conclusion, DAAM2-AS1 is a protein with significant implications for the development of drugs and biomarkers. Its unique structure and function make it an attractive target for drug development, and its expression in various tissues and diseases makes it a potential biomarker for various disorders. Further research is needed to fully understand the role of DAAM2-AS1 in disease progression and the development of new treatments.

Protein Name: DAAM2 Antisense RNA 1

The "DAAM2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DAAM2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets